All News

The Food and Drug Administration approved Kanjinti, a biosimilar to the US-licensed Herceptin, marking it the fifth of its kind.

An expert discusses the exciting approaches under investigation in mantle cell lymphoma and insight into where future research should focus.

How the company of a puppy provided the right amount of post-trauma comfort to help navigate in a post-cancer world.

Breast cancer was one of the best things that ever happened to me – and I never want it again. Now I am cancer-free and living a more fulfilling life than before the illness. Here are 10 insights and experiences from my cancer journey that continue to sustain me professionally and personally.

Only three short months after getting breast implants I would experience such severe and crippling symptoms that nearly cost me my life. This is not just another unsatisfactory online review.

The remarks posted by patients with cancer on the Internet can be skewed. Here are four tips to keep in mind when researching your condition and treatment options.

A nine-year breast cancer survivor and five-year melanoma survivor shares her thoughts on cancer survivorship with a side of mid-life crisis.

Like opposing wind fronts my emotions collided, spinning off a funnel of survivor guilt on a day I never thought would come.

The Food and Drug Administration approved Keytruda monotherapy and in combination with chemotherapy for the front-line treatments of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma.

Just as we tell the person that we love enduring cancer that they are not alone, as caregivers, neither are we.

Jennifer King, from the GO2 Foundation for Lung Cancer, discussed what patients can do to help address the stigma associated with lung cancer.

Here are three things I learned to avoid when recovering from cancer treatment.

The FDA has granted an accelerated approval to Polivy for use in combination with bendamustine and Rituxan for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma who have received at least two prior therapies.

Researchers determined that having difficulty performing at least one instrumental activity of daily living puts older patients at risk of death, unplanned hospitalization and emergency department visits.

This essay way written by Meaghan Connors from the Ann and Carl Myers Cancer Center, Radiation Oncology Department nominating registered nurse, LeSandra Bertch, for CURE®’s 2019 Extraordinary Healer® Award.

Making the choice to get busy living is often difficult for those with cancer, but the choice to start living your best life can be a good one. Each person must decide what that life looks like and when it’s time to start living it.

Evading the cancer issue is much easier.

From today’s top entertainers to racial disparities in access to pain treatment, here’s what is making headlines in the cancer space this week.

Why are men more likely to discover their breast cancer later than women?

In some cases, choosing the mundane can be life-giving, help salve emotional hurts and anchor our lives.

Recent study findings show no significant difference in treatment efficacy or overall survival between men and women.

Faith can be a tricky thing when you are dealing with cancer.

In a talk to people affected by melanoma, Michael McGrady described reassessing his values after cancer and how it changed the course of his life.

There is value in information being shared from survivor to survivor. Many health issues may be common, but you can feel alone if you are not aware of them. A well-moderated online support group may be a great place to gain knowledge and comfort.

Compared with single-agent therapy, the combination of Yervoy and Opdivo showed a 38% overall response rate.

We've got a sneak peek at what’s inside CURE®'s spring issue.

A devoted husband and caregiver shares the poetry he wrote for his beloved wife, Mary Lee, after doctors gave her 18 to 36 months to live.

The Food and Drug Administration granted a fast track designation to momelotinib for the treatment of patients with intermediate/high-risk myelofibrosis who have previously received a JAK inhibitor.

The Food and Drug Administration revealed its pilot program, designed to assist oncologists and patients requesting access to unapproved therapies in the cancer space.

Isn’t everyone a survivor from the time of diagnosis to the end? One reader thinks so.